Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
halometasone + tretinoin
- Development stage
- Unknown
- Lead developer
- Bright Future Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Kinnewer is a topical combination medication consisting of the potent group III corticosteroid halometasone (0.05%) and the retinoid tretinoin (0.05%). It is primarily utilized in China for the treatment of inflammatory and hyperkeratotic skin conditions, most notably palmoplantar pustulosis (PPP) and plaque psoriasis. The therapeutic efficacy of Kinnewer is derived from the synergistic action of its two active components: halometasone provides robust anti-inflammatory, anti-pruritic, and anti-exudative effects by activating glucocorticoid receptors, while tretinoin modulates epidermal cell turnover and keratinization by binding to retinoic acid receptors. This combination effectively addresses the scaling, erythema, and pustule formation characteristic of PPP. Clinical development and validation of this formulation have been significantly supported by research conducted at Ruijin Hospital, affiliated with Shanghai Jiaotong University.
- Brand names
- KinnewerJinniu'er
- Other names
- Halometasone/Tretinoin creamHalometasone and Tretinoin
02
Targets
GR (Glucocorticoid receptor)RARA (Retinoic acid receptor alpha)RXRA (Retinoid X receptor alpha)RAR (Retinoic acid receptor)
Beyond the preview
Go deeper on halometasone + tretinoin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on halometasone + tretinoin.